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Abstract
Natriuretic peptides (NP) are strongly associated with perioperative cardiovascular events. However, in patients with
raised NP, it remains unknown whether treatment to reduce NP levels prior to surgery results in better
perioperative outcomes. In this systematic review and meta-analysis, we investigate NP-directed medical therapy in
non-surgical patients to provide guidance for NP-directed medical therapy in surgical patients. The protocol was
registered with PROSPERO (CRD42017051468). The database search included MEDLINE (PubMed), CINAHL (EBSCO
host), EMBASE (EBSCO host), ProQuest, Web of Science, and Cochrane database. The primary outcome was to
determine whether NP-directed medical therapy is effective in reducing NP levels within 6 months, compared to
standard of care. The secondary outcome was to determine whether reducing NP levels is associated with
decreased mortality. Full texts of 18 trials were reviewed. NP-directed medical therapy showed no significant
difference compared to standard care in decreasing NP levels (standardized mean difference − 0.04 (− 0.16, 0.07)),
but was associated with a 6-month (relative risk (RR) 0.82 (95% confidence interval (CI) 0.68–0.99)) reduction in
mortality.
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Introduction
Every year, 230 million adults undergo non-cardiac sur-
gery worldwide (Weiser et al. 2008). In patients who are
45 years or older, 8% will suffer Myocardial Injury after
Non-cardiac Surgery (MINS) (Botto et al. 2014) and 2%
will die within 30 days (Devereaux et al. 2012). MINS is
typically asymptomatic without the usual features of
chest pain and electrocardiogram changes seen with
myocardial infarction (Botto et al. 2014). MINS has
prognostic importance up to a year after surgery (Puela-
cher et al. 2018).
The biomarker, B-type natriuretic peptide (BNP), has
been identified as an important preoperative predictor of
perioperative cardiovascular events (Rodseth et al. 2014).
Despite this strong association, it remains unknown
whether preoperative treatment to normalize or reduce
NP (B-type natriuretic peptide and N-terminal pro-B-
type natriuretic peptide) levels prior to surgery would re-
sult in improved perioperative outcomes. This is a novel
approach that has not been tested in clinical trials in-
volving surgical patients. Thus, a systematic review of
non-surgical trials is necessary to establish whether this
approach is safe and effective before it can be tested in a
surgical population.
The objective of this systematic review of clinical trials
was to determine whether, in adults, medical patients
with cardiac failure, NP-directed medical therapy is able
to decrease NP levels and whether this is associated with
increased survival.
These data could then be used to inform preoperative
protocols aimed at decreasing NPs prior to surgery, with
the intention of improving perioperative cardiovascular
outcomes.
Methods
Protocol and registration
The protocol was registered with PROSPERO
(CRD42017051468). The Preferred Reporting Items for
Systematic reviews and Meta-Analysis (PRISMA) guide-
lines were adhered to (Moher et al. 2009).
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Eligibility criteria
Clinical trials of adult medical patients who were ran-
domized to either NP guided medical therapy or stand-
ard care were eligible. We included trials which used
NPs to (i) guide medical therapy in non-surgical pa-
tients, (ii) up-titrate or modify medical therapy in the re-
sponse to NP levels, or (iii) included exercise as part of
cardiac rehabilitation in non-surgical patients. We re-
quired that the trials report the subsequent changes in
NP levels. We excluded trials that (i) monitored natri-
uretic peptides for prognostic or diagnostic purposes,
without a strategy to lower natriuretic peptide levels, (ii)
reviews of natriuretic peptide or biomarker physiology,
and (iii) trials reporting natriuretic peptides in patients
with acute myocardial infarction, pulmonary hyperten-
sion, cardiac resynchronization therapy, and left ven-
tricular devices.
Information sources, search, and study selection
Three searches were conducted using search terms
“brain natriuretic peptide” AND “treatment,” “brain
natriuretic peptide” AND “heart failure” and “brain
natriuretic peptide” AND “exercise.” The following data-
bases were accessed; MEDLINE (PubMed), CINAHL
(EBSCO host), EMBASE (EBSCO host), ProQuest, Web
of Science, and Cochrane database. No date filter was
used. An example of the search is shown in Additional
file 1. The initial search was conducted on 22 December
2016 and updated on the 4 March 2018.
Data collection process
Titles were screened for potential inclusion by CA and
PG. The abstracts of the potential papers identified
through the title search were then screened using inclu-
sion and exclusion criteria by CA and PG. The full texts
of potential trials were then extracted for detailed review
and analysis. Reference lists were searched for additional
papers that could be included in this review. Data ex-
traction was done by one author (CA) and then checked
by a co-author. When the required data was not pre-
sented in the publication, the authors were contacted for
these data.
Data items
We extracted data on the NP reduction within the first
six months of randomization and mortality at 6 months.
The data items extracted for this review are shown in
Additional file 1: Table S1.
Outcomes
The primary outcome for this review was to determine
whether a NP-directed medical therapy protocol is ef-
fective in reducing NP levels at 6 months after initiation
of therapy compared to standard care. The secondary
outcome was to determine whether NP-directed medical
therapy decreases mortality at 6 months and at the end
of the trial. The safety outcomes of changes in medical
therapy were evaluated. Specific medical treatment strat-
egies are described.
Risk of bias in individual studies
Assessment of bias in the studies was conducted by CA
and verified by BB following discussion. Each random-
ized trial was assessed using the Cochrane Collaboration
risk of bias tool, assessing selection bias, concealment
bias, performance bias, detection bias, attrition bias, and
other bias. Studies were assessed as having a low, un-
clear, or high risk of bias.
Summary measures and synthesis of results
The statistical analyses were conducted using Review
Manager Version 5.3 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014).
Those trials which had data on NP levels within 6
months of therapy initiation were analyzed using stan-
dardized mean difference (SMD), and these data are pre-
sented as a forest plot. Mean and standard deviation
(SD) of NP levels were used and those trials which re-
ported NP levels as the median and interquartile range
(IQR) were converted to mean and SD, using the for-
mula proposed by Wan et al. (Wan et al. 2014). Report-
ing the SMD allowed for the inclusion of all trials,
whether BNP or NT-proBNP, was used to monitor the
medical therapeutic response. SMD addresses the differ-
ence in the effect size for an intervention when the units
of measurement differ between trials e.g. use of BNP or
NT-proBNP. The SMD is the difference between groups
in the mean endpoint divided by the SD of the control
group or pooled SD of the treatment and control groups
(Hedges’ g) (Guyatt et al. 2015).
A meta-analysis of mortality within 6 months of the
initiation of therapy, with subgroup analyses at 4 and 6
months was conducted. The results are reported as rela-
tive risk (RR), with 95% confidence intervals (CI), and
presented as forest plots. Random effects models were
used where the I2 statistic > 2s5% (representing signifi-
cant heterogeneity), otherwise a fixed-effects model was
used.
Risk of bias across studies
Risk of bias across studies was assessed with funnel plots
for NP reduction and mortality.
Post hoc
After extracting and analyzing the data, it was noticed
that the methodology used in the exercise trials differed
significantly from the medical therapy trials. This differ-
ence was so substantial that we deemed it inappropriate
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to pool the two interventions. We therefore made a post
hoc decision to separate the exercise studies from the
medical therapy studies. These exercise study data are
presented in the accompanying publication (CS Alphon-
sus et al. 2019).
Results
Study selection
Sixty-four full-text articles were reviewed for potential
inclusion and 26 trials (presented in 27 publications)
met the inclusion criteria. An additional eight trials were
added from references (Fig. 1). Eighteen trials of medical
therapy interventions were identified (reported in 19
publications; 1 trial was reported in 2 separate papers)
(Maeder et al. 2013; Pfisterer et al. 2009) fulfilled the in-
clusion criteria, although only 14 trials provided data for
this review’s outcomes. The 16 exercise trials were sub-
sequently removed from this review, following the post
hoc decision to present these trials in a separate paper
(CS Alphonsus et. al. 2019).
We evaluated previous systematic reviews identified in
the search using the AMSTAR format (Additional file 1:
Table S2).
Study characteristics of included studies
The characteristics of the included clinical trials are
shown in Table 1. These trials included adult patients
of 18 years and older. The majority of the trials exam-
ined outpatient NP-directed medical therapy, with
follow-up of 15 months or more. In 10 out of 18 trials,
patients were seen by a specialist at a clinic (Anguita
et al. 2010; Berger et al. 2010; Eurlings et al. 2010;
Januzzi et al. 2011; Jourdain et al. 2007; Lainchbury
et al. 2009; Murdoch et al. 1999; Persson et al. 2010;
Schou et al. 2013; Shah et al. 2011; Troughton et al.
2000). Most patients were randomized once heart
Fig. 1 PRISMA flow diagram
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failure was medically stabilized and 12 out of 18 trials
enrolled patients with EF ≤ 50% (Beck-da-Silva et al.
2005; Felker et al. 2017; Januzzi et al. 2011; Jourdain
et al. 2007; Karlstrom et al. 2011; Murdoch et al. 1999;
Ozkara et al. 2007; Persson et al. 2010; Schou et al.
2013; Shah et al. 2011; Stienen et al. 2018; Troughton
et al. 2000). The remainder of the trials combined pa-
tients with preserved and reduced ejection fraction
(Anguita et al. 2010; Berger et al. 2010; Carubelli et al.
2016; Eurlings et al. 2010; Lainchbury et al. 2009; Mae-
der et al. 2013; Pfisterer et al. 2009).
The conduct of the trial intervention arms is shown in
Table 2. All trials randomized patients into NP-directed
medical therapy or clinical/usual care. Two trials were
three-arm trials, but for this analysis, only the interven-
tional and usual care arms were included (Berger et al.
Table 1 Characteristics of included clinical trials
Clinical trial Patients Intervention arm (n) vs
standard care arm (n)†
Follow-up (months)
Murdoch et al. (1999) Stable CHF, LVEF ≤ 35% BNP arm n = 10
Standard care n = 10
2
Troughton et al. (2000) Decompensated HF now stabilised, LVEF< 40% BNP arm n = 33
Standard care n = 36
9.5
Beck-da-Silva et al. (2005) > 18 years, stable CHF but not on β blockers, LVEF ≤ 40% BNP arm n = 21
Standard care n = 20
3
Jourdain et al. (2007) > 18 years, optimized on treatment, LVEF < 45% BNP arm n = 110
Standard care n = 110
15
Ozkara et al. (2007) Treated with ACEI/loop diuretic, LVEF ≤ 50% NT-proBNP arm n = 79‡
Standard care n = 61
6
Pfisterer et al. (2009) ≥ 60 years, LVEF≤v45%, 60–74 years=NT-proBNP
≥ 400 pg/ml; ≥ 75years = NT-proBNP 800 pg/ml
NT-proBNP arm n = 251
Standard care n = 248
18
Lainchbury et al. (2009)* > 18 years, AHF now stabilised NT-proBNP arm n = 121
Standard care n = 122
36
Anguita et al. (2010) > 18 years, AHF BNP arm n = 30
Standard care n = 30
18
Persson et al. (2010) LVEF < 50%, males NT-proBNP > 800 ng/ml, females>
1000 ng/ml
NT-proBNP arm n = 125
Standard care n = 127
9
Eurlings et al. (2010) AHF NT-proBNP > 1700, randomized at discharge if >
10% drop in NT-proBNP
NT-proBNP arm n = 174
Standard care n = 171
24
Berger et al. (2010)* AHF now stabilised, LVEF < 40% NT-proBNP + MC arm (only
patients with NT-proBNP > 2200
pg/ml) n = 92
Standard care n = 90
Maximum 18; minimum 12
Januzzi Jr et al. (2011) > 21 years, LVEF < 40% NT-proBNP arm n = 75
Standard care n = 76
10
Shah et al. (2011) Decompensation HF now stabilized, LVEF ≤ 35% BNP arm n = 68
Standard care n = 69
4
Karlstrom (2011) > 18 years; BNP > 150 ng/L for those aged < 75 years,
and BNP > 300 ng/L for those aged > 75 years
BNP arm n = 147
Standard care n = 132
33
Maeder et al. (2013) ≥ 60 years, LVEF > 45%, 60–74 years = NT-proBNP ≥
400 pg/ml; ≥ 75 years = NT-proBNP 800pg/ml
NT-proBNP arm n = 59
Standard care n = 64
18
Schou et al. (2013) > 18years, Optimised on treatment and implantable
ICD/CRT, LVEF < 45%, NT-proBNP > 1000
NT-proBNP arm n = 199
Standard care n = 208
Median 30
Carubelli et al. (2016) Randomized after stabilization of AHF NT-proBNP arm n = 137
Standard care n = 134
Mean 18
Stienen et al. (2018) Decompensated HF, NT-proBNP levels > 1700 ng/ml
within 24 h of hospital admission. In hospital intervention
NT-proBNP arm n = 201
Standard care n = 203
6
Felker et al. (2017) LVEF ≤ 40%, NT-proBNP > 2000 pg/mL/BNP > 400 pg/ml NT-proBNP arm n = 446
Standard care n = 448
12
CHF chronic heart failure, AHF-acute heart failure, NT-proBNP N-terminal pro b-type natriuretic peptide, LVEF left ventricular ejection fraction, ARB angiotensin II
receptor blocker, ACEI angiotensin converting enzyme inhibitor, ARA aldosterone receptor antagonist, B-blocker beta blocker, ICD/CRT implantable converter
defibrillator/cardiac resynchronisation therapy, BNP B-type natriuretic peptide, MC multidisciplinary care, NYHA New York Heart Association, HF heart failure
†Check Additional file 1
*Randomised to three-arm but only 2 meet the inclusion criteria for this review, NP-directed arm and control arm most reflecting usual patient care
‡ Only patients in the intervention arm received spironolactone
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2010; Lainchbury et al. 2009). In the majority of trials,
the NP threshold for inclusion was consistent across age
and gender, with the exception of three trials, where the
threshold was either age- or gender-specific (Karlstrom
et al. 2011; Maeder et al. 2013; Persson et al. 2010; Pfis-
terer et al. 2009). Nine trials set population NP targets
(Anguita et al. 2010; Berger et al. 2010; Carubelli et al.
2016; Felker et al. 2017; Januzzi et al. 2011; Jourdain
et al. 2007; Lainchbury et al. 2009; Murdoch et al. 1999;
Troughton et al. 2000), eight trials set individualized NP
targets (Beck-da-Silva et al. 2005; Eurlings et al. 2010;
Karlstrom et al. 2011; Maeder et al. 2013; Persson et al.
2010; Pfisterer et al. 2009; Schou et al. 2013; Shah et al.
2011; Stienen et al. 2018), and one trial had no set NP
target, but directed medical therapy to reduce the NP
level (Ozkara et al. 2007). The management of the stand-
ard care arms is shown in Additional file 1.
Two trials were stopped early (Felker et al. 2017;
Januzzi et al. 2011), Felker et. al for the benefit, and
Januzzi et al. for futility.
Risk of bias within studies and across studies
The risk of bias of the included trials is shown in Add-
itional file 1: Figures S1 and S2. The random sequence
generation was unclear in half the trials, and blinding of
patients and investigators was low. Many trials did not
clearly document if outcome assessors were blinded.
The funnel plots for SMD (Additional file 1: Figure S3),
and 6-month mortality (Additional file 1: Figure S4) did
not suggest publication bias.
Table 2 The conduct of the natriuretic-peptide (NP)-directed clinical trials
Clinical
Trial
Level of care in interventional group Frequency of visits NP target
Murdoch Specialist HF clinic Every 2 weeks Single target BNP< 50 pg/ml
Troughton Specialist HF clinic Every 3 months Single target N-BNP < 200 pmol/L
Beck-da-
Silva
Nurse-led HF clinic Every 3 months Individualized according to
symptoms in relation to BNP levels.
Jourdain Specialist care at the clinic 1 month (for 3 months) then 3 months Single target BNP < 100 pg/ml
Ozkara Physician clinic visits Treatment not adjusted throughout study No BNP target set
Lainchbury
*
Research clinic (with possible specialist
input)
Every 3 months Single target NT-proBNP < 150
pmol/L
Maeder;
Pfisterer
Outpatients visits 1, 3, 6, 12, 18 months NT-proBNP < 400 pg/ml in < 75 years
and < 800 pg/ml in ≥ 75 years
Eurlings Specialist care at the clinic 2 weeks, 1 month, then 3 months Individualized NT-proBNP < 10% of
randomization level
Berger * HF specialist clinic Every 2 weeks till NT-proBNP target met. Then as
required.
Single target NT-proBNP
< 2200 pg/ml
Persson Primary care centres 10 days, 1, 3, 6, 9 months Individualized NT-proBNP < 50%
from baseline level
Anguita Cardiology clinic 1, 2, 3, 6, 24, 18 months Single target BNP < 100 pg/ml
Shah HF clinic with specialist input 1 week, 1, 2, 3, 4 months after discharge Individualized BNP < 2 times
discharge level
Januzzi HF clinic Every 3 months Single target NT-proBNP ≤
1000 pg/ml
Karlstrom Outpatient visits 2, 6, 10, 16, 2, 36, 48 weeks, then every 6 months < 75 years (BNP < 15 ng/L)
and ≥75yrs (BNP < 300 ng/L)
Schou Specialist heart failure clinic Every 1–3 months Individualised NT-proBNP < 30%
of randomization level
Carubelli Single center, initially in hospital
management and then outpatient
visits
Frequent visits if NT-proBNP still raised after discharge.
Then telephonic follow up at 1, 3, and 6 months
Single target NT-proBNP≤ 3000
pg/ml
Felker Outpatient visits 2 and 6 weeks, then every 3 months Single target NT-proBNP
< 1000 pg/mL.
Stienen Intervention carried out in the hospital 1 week and at 1, 3, and 6 months Individualized to reduce
NT-proBNP by at least 30% by
discharge
NP natriuretic peptide, NT-proBNP N-terminal pro B-type natriuretic peptide, LVEF left ventricular ejection fraction, ARB angiotensin II receptor blocker,
ACEIangiotensin-converting enzyme inhibitor, BNP B-type natriuretic peptide, NYHA New York Heart Association, HF heart failure
*Lainchbury and Berger: three-arm trial but only NT-proBNP guided management group and usual care group compared
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Results of individual studies and synthesis of results
The efficacy of an NP-directed medical therapy in reducing
NP levels within 6 months compared to standard care
Fourteen out of 18 medical therapy trials presented data
on change in NP levels during the trial (Anguita et al.
2010; Carubelli et al. 2016; Eurlings et al. 2010; Felker
et al. 2017; Januzzi et al. 2011; Jourdain et al. 2007; Karl-
strom et al. 2011; Lainchbury et al. 2009; Maeder et al.
2013; Murdoch et al. 1999; Persson et al. 2010; Pfisterer
et al. 2009; Schou et al. 2013; Shah et al. 2011; Stienen
et al. 2018; Troughton et al. 2000), of which 7 out of 14
trials presented data on NP levels within the first 6
months of the trial (Anguita et al. 2010; Carubelli et al.
2016; Felker et al. 2017; Maeder et al. 2013; Pfisterer
et al. 2009; Shah et al. 2011; Stienen et al. 2018). Three
trials Shah, Carubelli, and Stienen were excluded as the
data was reported at differing time points before 6
months: Stienen (mean 12 ± 10 days) (Stienen et al.
2018), Carubelli (mean 11 ± 9 days) (Carubelli et al.
2016) and Shah (4 months) (Shah et al. 2011). The over-
all point estimate of the four remaining trials was non-
significant at 6 months of NP-directed medical therapy
with low heterogeneity in the included trials (Fig. 2),
(SMD − 0.04, 95% CI − 0.16, 0.07).
Reduction in NP levels and its association with mortality
Seventeen out of 18 studies reported mortality at trial
completion (Anguita et al. 2010; Beck-da-Silva et al.
2005; Berger et al. 2010; Carubelli et al. 2016; Eurlings
et al. 2010; Felker et al. 2017; Januzzi et al. 2011; Jour-
dain et al. 2007; Karlstrom et al. 2011; Lainchbury et al.
2009; Maeder et al. 2013; Ozkara et al. 2007; Persson
et al. 2010; Pfisterer et al. 2009; Schou et al. 2013; Shah
et al. 2011; Stienen et al. 2018; Troughton et al. 2000).
After extracting the end of trial mortality data, it was
deemed inappropriate to conduct a meta-analysis, as the
duration of the trial follow up periods differed between
the trials. It was therefore impossible to conduct a meta-
analysis at a fixed long-term time point.
Eight of the 18 trials (Anguita et al. 2010; Eurlings
et al. 2010; Felker et al. 2017; Lainchbury et al. 2009;
Maeder et al. 2013; Pfisterer et al. 2009; Shah et al. 2011;
Stienen et al. 2018) reported mortality within the first 6
months of the intervention. Two trials reported mortal-
ity at 4 months, and 6 trials reported mortality at 6
months. NP-directed medical therapy was associated
with a reduction in mortality within the first 6 months
of the intervention (RR 0.82, 95% CI 0.68–0.99). Sub-
group analysis suggested little heterogeneity between the
4-month and 6-month outcomes (Fig. 3).
Adverse events in relation to the change in therapy
Seven out of 18 studies recorded adverse effects of medical
therapy on electrolytes and the cardiovascular system
(Eurlings et al. 2010; Januzzi et al. 2011; Jourdain et al.
2007; Maeder et al. 2013; Murdoch et al. 1999; Pfisterer
et al. 2009; Shah et al. 2011; Troughton et al. 2000). These
were deemed not serious and six of these studies showed
no difference in the incidence of adverse effects of therapy
between the intervention and control groups.
The specific treatment strategies used in the trials
The treatment strategies and efficacy of these treatments
varied between the trials. The two trials that showed the
most benefit associated with NP-directed medical ther-
apy,(Carubelli et al. 2016) and (Shah et al. 2011), showed
efficacy for diuretics (the former) and angiotensin-
converting enzyme inhibitors and beta-blockers (the lat-
ter). The two studies that showed the greatest number
of patients reaching target NP levels, (Lainchbury et al.
2009) and (Karlstrom et al. 2011), showed that a com-
bination of therapies was effective, including diuretics,
angiotensin-converting enzyme inhibitor/angiotensin II
receptor blockers and beta-blockers.
Discussion
The principal findings of this systematic review are that
NP-directed medical therapy does not significantly re-
duce NP levels at 6 months after initiation of NP-
Fig. 2. Efficacy of natriuretic peptide-directed medical therapy versus control in reducing BNP-levels within 6 months(Standardised mean
difference in natriuretic peptide levels in NP-directed medical therapy clinical trials). SD, standard deviation; CI, confidence interval
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directed medical therapy. However, NP-directed medical
therapy may be associated with decreased mortality in
the short term, and there is little heterogeneity for this
finding.
Strengths
The strength of this review is that we evaluated the effi-
cacy of NP-directed medical therapy from clinical trials,
on the biochemical response of patient NP levels, and
the clinically relevant outcome of mortality. The meth-
odology of this systematic review and meta-analysis is
robust.
Findings in relation to other studies
There is an important fundamental difference between
this meta-analysis, and the other two meta-analyses that
were published after the protocol for our meta-analysis
was registered (Khan et al. 2018; Pufulete et al. 2017).
The primary outcome of our meta-analysis was to evalu-
ate if it was possible to decrease NP levels with NP-
directed therapy, while the primary outcome of the other
two meta-analyses was to determine if NP-directed med-
ical therapy was associated with a survival benefit. Evalu-
ation of a potential survival benefit was a secondary
outcome in our meta-analysis. Our primary interest was
to determine whether perioperative physicians could
possibly decrease NP levels prior to elective surgery in
patients with high NP levels (and thereby potentially im-
prove the risk profile of poor surgical candidates). Both
these meta-analyses also had point estimates favoring
survival benefit with NP-directed therapy in the long
term. The importance of our meta-analysis is that (i) a
reduction in NP levels is not necessarily essential to
demonstrate a survival benefit with NP-directed medical
therapy, and (ii) that this survival benefit may be seen
earlier than what has been previously documented. The
utility of NP-directed medical therapy in preoperative
surgical patients is unknown, as there are currently no
surgical trials in this field. This meta-analysis suggests
that there is potential utility in this approach in surgical
patients.
Preoperative risk stratification of high-risk patients is
advocated by international guidelines, the most recent be-
ing the Canadian Cardiovascular Society Guidelines on
Perioperative Cardiac Risk Assessment and Management
for Patients Who Undergo Noncardiac Surgery (Duceppe
et al. 2017). Screening for natriuretic peptides is a key
component of risk stratification (Duceppe et al. 2017).
Our meta-analysis suggests that there may be a further
benefit to the reduction of NP levels prior to surgery. The
survival benefit seen with NP-directed medical therapy in
this meta-analysis may suggest that an intensification of
medical therapy is warranted in patients with marked
physiological derangement reflected by a markedly
Fig. 3 Effect of natriuretic peptide guided medical therapy versus control on mortality after 6 months. CI-confidence interval
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elevated NP level. These high NP levels may reflect some
reversibility in volume status and myocyte ischemia which
is responsive to further medical therapy. Indeed, the trials
which demonstrated the greatest number of patients
reaching a target NP level included a combination of ther-
apies which would have had both volume and ischemia ef-
ficacy (Karlstrom et al. 2011; Lainchbury et al. 2009). The
importance of this systematic review is the following.
Firstly, these findings suggest that there is potential to im-
prove survival for an elective surgical population through
NP-directed medical therapy. Secondly, the perioperative
period is a powerful modifier of risk, and decreasing this
risk, has the potential to change morbidity and mortality
up to a year after surgery (Puelacher et al. 2018).
Limitations
We were unable to obtain data from all the included
trials for the SMD, the patients reaching the target NP
and the time to NP reduction analysis. This is because
most trials did not publish these end-points, nor was
this included as part of the trial protocols. It is possible
that if we had a larger sample which included data from
all trials, then we may have shown an association be-
tween NP-directed medical therapy and a reduction in
NP levels. However, it appears from this meta-analysis,
that it is the intensification of medical therapy, rather
than the reduction in NP levels, which may be import-
ant for short-term survival.
The non-parametric data for the SMD analysis was
transformed to mean and standard deviation to facilitate
analysis and caution should be taken when interpreting
these results. The range of starting NP level on
randomization in the intervention groups is large and
could dramatically influence responsiveness to NP-
directed therapy. However, despite these differences in
the pre-intervention NP levels, mortality decreased in
the NP-directed therapy arm, with little heterogeneity. It
could be argued, however, that this early mortality (i.e.,
at 6 months of therapy initiation) signal is fragile. If a
random-effects meta-analysis is conducted, then one
cannot demonstrate a survival benefit associated with
NP-directed medical therapy (RR 0.88, 95% 0.75–1.04, p
= 0.14). Similarly, a sensitivity analysis which excludes
all trials with a high risk of bias is not associated with a
survival benefit (RR 0.84, 95% CI 0.61–1.15, p = 0.27) in
a random-effects model. The survival benefit demon-
strated in this meta-analysis therefore should be consid-
ered “hypothesis-generating” at best. It was not possible
to control for the effect of age or renal function on NP
for this analysis.
Finally, the included trials had very different imple-
mented protocols, and thus it is not possible to iden-
tify a preferred medical management plan based on
these data.
Future research
This systematic review provides support for a clinical
trial of preoperative NP-directed medical therapy in
high-risk elective surgical patients.
Conclusion
NP-directed medical therapy does not necessarily de-
crease NP levels, but it may be associated with a survival
benefit. There may be a place for preoperative NP-
directed medical therapy in high-risk surgical patients.
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